Treatment of gastroduodenal Crohn's disease

Digestion. 2005;71(1):37-40. doi: 10.1159/000083871. Epub 2005 Feb 4.

Abstract

Symptomatic gastroduodenal manifestations of Crohn's disease (CD) are rare, with less than 4% of patients being clinically symptomatic. Gastroduodenal involvement may, however, be found endoscopically in 20% and in up to 40% of cases histologically, most frequently as Helicobacter pylori-negative focal gastritis, usually in patients with concomitant distal ileal disease. In practice, the activity of concomitant distal CD usually determines the indication for therapy, except in the presence of obstructive gastroduodenal symptoms. With the few data available, it seems correct to say that localized gastroduodenal disease should be treated with standard medical therapy used for more distal disease, with the exception of sulfasalazine and mesalanine with pH-dependent release. Presence of symptoms of obstruction needs aggressive therapy. If medical therapy with steroids and immunomodulatory drugs does not alleviate the symptoms, balloon dilation and surgery are the options to consider.

Publication types

  • Review

MeSH terms

  • Catheterization
  • Crohn Disease / complications
  • Crohn Disease / therapy*
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunologic Factors / therapeutic use*
  • Intestinal Obstruction / etiology
  • Intestinal Obstruction / therapy
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Immunologic Factors